The FDA approved a label update with a new titration schedule for donanemab (Kisunla), an anti-amyloid drug approved to treat early symptomatic Alzheimer's disease, drugmaker Eli Lilly said. The move ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results